- Home
- / Adial Pharmaceuticals
Adial Pharmaceuticals
Stock Price
$1
2024-10-29
Market Capitalization
$6.7 M
2024-10-29
Adial Pharmaceuticals Summary
Company Summary
- Overview
- Adial Pharmaceuticals engages in the development of prescription medications for addiction and related disorders in the United States. The Company's research pipeline includes AD04, a compound that completed Phase IIb study for the treatment of alcohol use disorders; and AD01, which completed Phase I clinical stage for treating addictive behaviors.
- Type
- Public
- Status
- Active
- Founded
- 2010
- HQ
- Charlottesville, VA, US | view all locations
- Website
- http://www.adialpharma.com/
- Cybersecurity rating
Table of Contents
Key People
Kevin Schuyler, Vice Chairman & Lead Independent Director
James W. Newman, Director
Alex Lugovoy, Chief Business Officer
LocationsView all
2 locations detected
Charlottesville, VA HQ
United States
204 E High St
Charlottesville, VA
United States
1180 Seminole Trail #495
Adial Pharmaceuticals Financials
Summary Financials
- Net income (Q1, 2026)
- ($2.0M)
- Cash (Q1, 2026)
- $4.6M
- EBIT (Q1, 2026)
- ($2.0M)